https://www.odysseyneuroscience.com/neuromind-biopharma-announces-the-approval-of-mescaline-study/2025-10-13T07:56:44+00:00https://www.odysseyneuroscience.com/neuromind-biopharma-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial/2025-10-13T07:55:38+00:00https://www.odysseyneuroscience.com/neuromind-biopharma-announces-appointment-of-dr-sarah-y-vinson-as-additional-director/2025-10-13T07:54:36+00:00https://www.odysseyneuroscience.com/can-lsd-cure-our-pandemic-anxiety-neuromind-biopharma-is-spending-big-to-find-out/2025-10-13T07:53:35+00:00https://www.odysseyneuroscience.com/this-company-is-working-on-a-drug-that-will-make-lsd-less-trippy/2025-10-13T07:52:33+00:00https://www.odysseyneuroscience.com/psychedelic-drug-company-mindmed-applies-for-nasdaq-up-listing/2025-10-13T07:51:37+00:00